Overview
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Eligibility
Inclusion Criteria:
- Be ≥ 18 and ≤ 55 years of age
- Diagnosis of keratoconus in the study eye
Exclusion Criteria:
- Pregnant, lactating or planning a pregnancy
- Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial


